Oncology Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncology Pharma, Inc.
Deal Watch: AI Specialist Biolojic Inks Diabetes Pact With Lilly, Autoimmune Tie-Up With Nektar
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Oncology Sciences Corp.
Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.
Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.
- Other Names / Subsidiaries
- SourcingLink.net, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.